Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 323 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pelvic Malignancies Clear all
Terminated Phase 2 Interventional Results available

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

NCT00363883
View directory record Official record
Conditions
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Cell Carcinoma of the Bladder
Interventions
vorinostat, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Jun 25, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT03397394
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Results available

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

NCT02812186
View directory record Official record
Conditions
Cholecystitis, Endometriosis, Bowel Obstruction, Fibroids, Prostate Cancer, Chronic Kidney Disease, Uterine Prolapse
Interventions
Deep to Moderate NMB, Moderate to Deep NMB, Rocuronium
Procedure · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Jun 25, 2026, 5:32 AM EDT
Active, not recruiting Not applicable Interventional

A Study of Near-Infrared Fluorescence Imaging With ICG During Reconstructive Gynecologic Surgery

NCT05071976
View directory record Official record
Conditions
Gynecologic Surgery
Interventions
ICG-NIR angiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 25, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional

Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy

NCT07419490
View directory record Official record
Conditions
Colorectal (Colon or Rectal) Cancer, Pelvic Malignancies, Oncofertility
Interventions
Uteroovarian transposition
Procedure
Lead sponsor
University of South Florida
Other
Eligibility
18 Months to 40 Months · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 5:32 AM EDT
Active, not recruiting Not applicable Interventional

Improving Women's Function After Pelvic Radiation

NCT04544735
View directory record Official record
Conditions
Sexual Dysfunction, Pelvic Floor Disorders, Gynecologic Cancer
Interventions
Integrated Physical Therapy and Coping Skills Training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 25, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT05874921
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions
Jelmyto (mitomycin) for pyelocalyceal solution
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Jun 25, 2026, 5:32 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

NCT00005958
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Surveillance Pelvic Examination Anxiety: Brief Coping Skills Intervention

NCT05285306
View directory record Official record
Conditions
Anxiety
Interventions
PEACE Program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

NCT00407485
View directory record Official record
Conditions
Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
ziv-aflibercept, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2014 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

NCT00661609
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Bladder Cancer, Urethra Cancer, Ureter Cancer, Renal Pelvis Cancer
Interventions
AZD4877
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Palo Alto, California • San Bernardino, California • Southington, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

NCT01832259
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Pazopanib, Placebo
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Early Phase 1 Interventional Results available

Intensity Modulated Radiation Therapy for Prostate Cancer

NCT00214422
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Jun 25, 2026, 5:32 AM EDT
Completed No phase listed Observational

Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy

NCT00508703
View directory record Official record
Conditions
Uterine Cancer, Cervical Cancer, Endometrial Cancer
Interventions
Intensity Modulated Radiotherapy (IMRT), CT Scan
Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Jun 25, 2026, 5:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer

NCT05100472
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

NCT01536392
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Granisetron, Ondansetron, Questionnaires, Study Drug Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 25, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

NCT01353222
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
DN24-02, Standard of Care
Biological · Other
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
60
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Jun 25, 2026, 5:32 AM EDT
Recruiting Phase 3 Interventional

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

NCT06915727
View directory record Official record
Conditions
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm, Malignant Pelvic Neoplasm, Metastatic Childhood Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium, Surgical Procedure
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Months to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer

NCT00084773
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cetuximab, fluorouracil, neoadjuvant therapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients

NCT00359866
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
IMRT with tomotherapy
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Jun 25, 2026, 5:32 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Feasibility and Safety of Single Port Robot in Colorectal Procedures

NCT03700593
View directory record Official record
Conditions
Colon Cancer, Colon Polyp, Rectal Cancer, Diverticulitis, Prolapse, Rectal, Rectal Polyp, Inflammatory Bowel Diseases
Interventions
Single Port Robotic Colorectal Surgery
Device
Lead sponsor
Marks Colorectal Surgical Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jun 25, 2026, 5:32 AM EDT
Completed No phase listed Observational

Urology Database for Outcomes Research

NCT00444730
View directory record Official record
Conditions
Prostate Cancer, Pelvic Pain, Incontinence
Interventions
Radical Prostatectomy, InterStim Implantation, Pelvic organ prolapse repair
Procedure
Lead sponsor
Kenneth Peters, MD
Other
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Jun 25, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking

NCT05977621
View directory record Official record
Conditions
Uterine Cancer
Interventions
Transrectal ultrasound (TRUS)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 25, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis

NCT01757717
View directory record Official record
Conditions
Metastatic or Recurrent Lesions in the Spine, Metastatic or Recurrent Lesions in the Pelvis
Interventions
Ir-192 high dose rate (HDR)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jun 25, 2026, 5:32 AM EDT